GlassScriptPhysician profile
Suzanne C Wetherold
NPI 1710993431
$2,608.20
in general payments reported to CMS, 2019-2025
19 companies · $335 in 2025
The $335 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $58.68 · 2021: $171 · 2022: $224 · 2023: $244 · 2024: $475 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.95 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $923.63 | 2019-2025 | Ozempic |
| Actelion Pharmaceuticals US, INC. | $308.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $234.53 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $218.14 | 2019 | |
| Pfizer INC. | $168.74 | 2024-2025 | |
| Abiomed | $123.08 | 2019-2024 | Impella |
| Alnylam Pharmaceuticals INC. | $121.83 | 2023-2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $86.97 | 2023 | Optimizer |
| Boston Scientific Corporation | $85.12 | 2019 | |
| Lilly USA, LLC | $75.02 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $71.72 | 2025 | |
| Currax Pharmaceuticals LLC | $53.21 | 2019-2025 | Contrave |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.64 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $29.23 | 2021 | |
| Chiesi USA, INC. | $28.26 | 2020-2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $25.81 | 2023-2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $14.21 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Wetherold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.